Close

Enlivex Therapeutics Ltd. (ENLV) Granted Two US Patents Covering Methods of Treating Sepsis with Allocetra

Go back to Enlivex Therapeutics Ltd. (ENLV) Granted Two US Patents Covering Methods of Treating Sepsis with Allocetra

Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

May 5, 2022 8:37 AM EDT

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property (IP) protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with AllocetraTM.   

Oren Hershkovitz, PhD, CEO of Enlivex, stated, These latest patents add important depth to the IP portfolio protecting our sepsis program, with one specifically covering the treatment of sepsis derived from pneumonia, urinary, or biliary tract infections. These are three important... More